AKTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

AKTX ▲ +48.47% at T+20d

LONG call ✓ call won +48.47% · α vs SPY +40.90% · entry $3.92 → $5.82

Next anchor: T+60d in 21d

Last close $13.40 (close Jun 12) · +241.84% from $3.92 entry

Entry anchored
Apr 8, 03:59 PM ET
via Databento tick

T+1d

-2.30%

call -2.30% · α -2.23%

$3.83

settled 2mo ago

T+5d

+30.61%

call +30.61% · α +27.43%

$5.12

settled 2mo ago

T+20d

+48.47%

call +48.47% · α +40.90%

$5.82

settled 6w ago

T+60d

—

call — · α —

—

in 21d

Price Chart

Loading chart...

Executive Summary

Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate development of its antibody drug conjugate (ADC) programs, particularly AKTX-101, with an anticipated IND filing by late 2026. The collaboration enhances platform validation and reduces execution risk, positioning Akari within the growing ADC landscape.

Actionable Insight

Traders should monitor upcoming IND submission for AKTX-101 as a near-term catalyst; the WuXi XDC partnership reduces technical risk and may attract future licensing interest, especially given PH1's novel mechanism in a high-demand ADC market.

Key Facts

Strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing
Partnership extends beyond traditional CDMO engagement, supporting accelerated development
AKTX-101 IND filing expected in late 2026, with first-in-human trials by late 2026/early 2027
PH1 payload platform validated through collaboration, enabling efficient advancement of ADC candidates

Financial Impact

Non-dilutive strategic collaboration enhancing development efficiency and de-risking clinical advancement

dilutionexecution riskdevelopment timeline

Risk Factors

Dependence on successful IND acceptance and clinical trial initiation
Need for additional capital to fund development beyond current milestones

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3270992

8 reports for AKTX

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +38.48%Apr 16, 2026

Filters

Reports for AKTX — sortable, filterable
	Type				Now
May 28, 2026 17d ago	Press Release NEUTRAL ★ 4/10	$22.05 $14.99	▼ −32.04%	▼ −31.99%	$13.40 (−39.23%)
May 22, 2026 23d ago	8-K BEARISH ★ 7/10	$17.81 $13.43	▲ +24.59%	▲ +25.68%	$13.40 (+24.76%)
May 21, 2026 24d ago	Press Release BEARISH ★ 6/10	$5.14 $22.05	▼ −328.99%	▼ −327.39%	$13.40 (−160.70%)
May 12, 2026 4w ago	Press Release NEUTRAL ★ 4/10	$3.06 $3.50	▲ +14.38%	▲ +14.30%	$13.40 (+337.91%)
Apr 16, 2026 8w ago	EFFECT BEARISH ★ 7/10	$5.12 $6.00	▼ −17.19%	▼ −16.20%	$13.40 (−161.72%)
Apr 9, 2026 9w ago	Press Release BULLISH ★ 6/10	$3.92 $5.12	▲ +30.61%	▲ +27.43%	$13.40 (+241.84%)
Apr 6, 2026 9w ago	Press Release NEUTRAL ★ 4/10	$3.54 $4.25	▲ +20.00%	▲ +15.87%	$13.40 (+278.53%)
Mar 17, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$6.52 $5.48	▼ −15.95%	▼ −15.24%	$13.40 (+105.52%)

US Market Status

Market Closed — Opens in 5h 3m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access